Non-responsive celiac disease (NRCD) is relatively common. It is generally attributed to persistent gluten exposure and resolves after correction of diet errors. However, other complications of CD and disorders clinically mimicking CD, need to be excluded. Novel therapies are being evaluated to facilitate mucosal recovery, which might benefit NRCD patients. Refractory CD (RCD) is rare and is currently divided into two types. The etiology of RCD type 1 (RCDI) is unclear, a possible switch to gluten-independent autoimmunity is suspected in some patients, while RCD type II (RCDII) represents a low-grade intraepithelial lymphoma.
We will be happy to hear your thoughts